TANGO THERAPEUTICS, INC.

Insiders Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
6.92 ^USD	+3.90%		+0.14%	-30.10%

May. 28	HC Wainwright Adjusts Price Target on Tango Therapeutics to $13 From $17, Maintains Buy Rating	MT
May. 24	Guggenheim Adjusts Tango Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

British billionaire Joe Lewis fined $5 million by US judge for insider trading	Apr. 04	RE
Multibillionaire Joe Lewis to face US sentencing for insider trading	Apr. 04	RE
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	Jan. 24	RE
Tango Therapeutics, Inc. Announces Board Changes	Nov. 08	CI
Tango Therapeutics, Inc. Announces Board Changes	23-08-29	CI
Tango Therapeutics, Inc. Announces Alan Huang, Ph.D., the Company's Chief Scientific Officer, Intends to Transition Out of His Role as Chief Scientific Officer	23-08-07	CI
Tango Therapeutics, Inc. Announces the Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development	23-02-28	CI
Tango Therapeutics, Inc. Appoints Aaron Weitzman as Chief Medical Officer	22-11-10	CI
Tango Therapeutics Appoints Dr. Michael Palmieri as Head of CMC	22-01-24	CI
Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer	21-11-01	CI
BCTG Acquisition Corp. Announces Executive Resignations	21-04-14	CI
BCTG Acquisition Corp. Appoints James B. Avery to the Board as a Class 3 Director	20-10-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer